This statistic displays the value of finished drugs imported into South Korea in 2015, by efficacy group. During the measured time period, South Korea imported anti-tumor drugs the most, amounting to around 454 million U.S. dollars.
Value of finished drugs imported into South Korea in 2015, by efficacy group (in million U.S. dollars)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Basic Statistic U.S. adults that have not heard of personalized medicine 2018
- Basic Statistic Reactions among U.S. adults to description of personalized medicine 2018
- Basic Statistic U.S. opinions on insurance coverage of personalized tests and treatments in 2018
- Basic Statistic Major concerns among adults regarding personalized medicine in the U.S. in 2018
- Premium Statistic Boehringer Ingelheim's top prescription drugs 2020-2022
- Basic Statistic Projection of global revenue for orphan prescription drugs 2016-2028
- Basic Statistic Orphan drug sales worldwide by therapy category 2028
- Basic Statistic Orphan vs. non-orphan pipeline sales forecast worldwide 2023-2028
- Premium Statistic Top 10 expensive drugs in Canada by annual cost per beneficiary 2021/2022
- Basic Statistic Level 1 ATC therapy classes by share of total public drug costs in Canada 2021/2022
About the region
10
- Premium Statistic Cholesterol drugs estimated market size in South Korea 2014-2020
- Premium Statistic Anti-cancer drugs estimated market size in South Korea 2014-2020
- Premium Statistic Anti-diabetics estimated market size in South Korea 2014-2020
- Premium Statistic Cardiovascular disease drugs estimated market size in South Korea 2014-2020
- Premium Statistic Biopharmaceutical import value in South Korea 2012-2022
- Premium Statistic Sales revenue Celltrion 2013-2022
- Premium Statistic Sales revenue Yuhan 2015-2022
- Premium Statistic Market share of Celltrion's Remsima in Europe Q1 2015-Q2 2018
- Premium Statistic Market share of Celltrion's Truxima in Europe Q2 2017-Q2 2018
- Premium Statistic Most common prescription drugs for prostatic hyperplasia South Korea 2016
Selected statistics
6
- Premium Statistic Expenditure worldwide on diabetes by market 2013-2018
- Premium Statistic Medicinal market growth worldwide including rebates 2009-2018
- Basic Statistic AstraZeneca's revenue from top product Pulmicort 2006-2023
- Premium Statistic Chinese insulin market distribution: leading companies 2011
- Premium Statistic U.S. insulin market distribution: leading companies 2011
- Premium Statistic Standard Unit medicine use per capita in the U.S. 2007-2011
Other regions
10
- Premium Statistic Top therapy classes by spending global market 2027 forecast
- Premium Statistic Biologic drug costs in select Canadian public drug plans in 2021/2022
- Premium Statistic Sino Biopharm annual revenue 2013-2022
- Basic Statistic Compensation of dispensed thyroid in the Netherlands per user 2014-2022
- Basic Statistic R&D expenditure per employee in U.S. sectors 2003-2017
- Basic Statistic Share of Mexican medical device exports in 2016, by product
- Basic Statistic Pharmacy market revenue in Germany 2010-2022
- Premium Statistic Potential biosimilars savings in EU5 countries and the U.S. 2016-2020
- Basic Statistic Canadian vs US price difference of select oral solid opioids 2017
- Basic Statistic Cardiovascular system pharmaceutical consumption in Belgium 2008-2021
Related statistics
9
- Premium Statistic BPH outpatient prescription medicine sales in South Korea 2016, by age group
- Premium Statistic Parenteral nutrition company market share in South Korea 2015
- Premium Statistic Leading pharmaceutical businesses South Korea 2022, by revenue
- Premium Statistic R&D spending of JW Pharmaceutical South Korea 2014-2022
- Premium Statistic R&D spending ratio of JW Pharmaceutical South Korea 2014-2022
- Premium Statistic Sales revenue distribution of JW Pharmaceutical South Korea 2022, by channel
- Premium Statistic Sales revenue of JW Pharmaceutical 2014-2022
- Premium Statistic Operating profit of JW Pharmaceutical 2014-2022
- Premium Statistic Sales revenue of GC Pharma 2015-2023
Further related statistics
9
- Merck & Co - expenditure on research and development 2006-2023
- Merck & Co total assets 2009-2023
- GSK's operating profit by division 2006-2021
- Sanofi's total assets 2007-2023
- Pfizer's revenues in the U.S. and abroad 2009-2023
- Key figures on established biotech centers worldwide 2012-2016
- Global pharmaceutical pipeline by therapy area 2013-2017
- Medicare - number of skilled nursing facilities in the U.S. 1967-2021
- Merck & Co cash dividends declared 2006-2023
Further Content: You might find this interesting as well
Statistics
- Merck & Co - expenditure on research and development 2006-2023
- Merck & Co total assets 2009-2023
- GSK's operating profit by division 2006-2021
- Sanofi's total assets 2007-2023
- Pfizer's revenues in the U.S. and abroad 2009-2023
- Key figures on established biotech centers worldwide 2012-2016
- Global pharmaceutical pipeline by therapy area 2013-2017
- Medicare - number of skilled nursing facilities in the U.S. 1967-2021
- Merck & Co cash dividends declared 2006-2023
KOTRA (Invest KOREA). (July 13, 2017). Value of finished drugs imported into South Korea in 2015, by efficacy group (in million U.S. dollars) [Graph]. In Statista. Retrieved April 24, 2024, from https://www.statista.com/statistics/886312/south-korea-finished-drug-import-value-by-efficacy-group/
KOTRA (Invest KOREA). "Value of finished drugs imported into South Korea in 2015, by efficacy group (in million U.S. dollars)." Chart. July 13, 2017. Statista. Accessed April 24, 2024. https://www.statista.com/statistics/886312/south-korea-finished-drug-import-value-by-efficacy-group/
KOTRA (Invest KOREA). (2017). Value of finished drugs imported into South Korea in 2015, by efficacy group (in million U.S. dollars). Statista. Statista Inc.. Accessed: April 24, 2024. https://www.statista.com/statistics/886312/south-korea-finished-drug-import-value-by-efficacy-group/
KOTRA (Invest KOREA). "Value of Finished Drugs Imported into South Korea in 2015, by Efficacy Group (in Million U.S. Dollars)." Statista, Statista Inc., 13 Jul 2017, https://www.statista.com/statistics/886312/south-korea-finished-drug-import-value-by-efficacy-group/
KOTRA (Invest KOREA), Value of finished drugs imported into South Korea in 2015, by efficacy group (in million U.S. dollars) Statista, https://www.statista.com/statistics/886312/south-korea-finished-drug-import-value-by-efficacy-group/ (last visited April 24, 2024)
Value of finished drugs imported into South Korea in 2015, by efficacy group (in million U.S. dollars) [Graph], KOTRA (Invest KOREA), July 13, 2017. [Online]. Available: https://www.statista.com/statistics/886312/south-korea-finished-drug-import-value-by-efficacy-group/